The grades of 8 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This is a strong week for Intercept Pharmaceuticals, Inc. (ICPT). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

This week, MacroGenics, Inc.’s (MGNX) ratings are up from a C last week to a B. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

Cara Therapeutics Inc (CARA) gets a higher grade this week, advancing from a B last week to a A. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of CARA stock.

Trevena, Inc.’s (TRVN) ratings are looking better this week, moving up to a A from last week’s B. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Sinovac Biotech Ltd. (SVA) boosts its rating from a C to a B this week. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of SVA stock.

Minerva Neurosciences Inc (NERV) shows solid improvement this week. The company’s rating rises from a C to a B. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of NERV stock.

This week, OncoGenex Pharmaceuticals, Inc. (OGXI) pushes up from a C to a B rating. OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. For more information, get Portfolio Grader’s complete analysis of OGXI stock.

Harvard Apparatus Regenerative Technology, Inc. (HART) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of HART stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.